<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Kinase Inhibitors </title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="bootstrap-superhero.css">
    <link rel="stylesheet" href="style.css">
    <script src="https://code.jquery.com/jquery-3.3.1.slim.min.js" integrity="sha384-q8i/X+965DzO0rT7abK41JStQIAqVgRVzpbzo5smXKp4YfRvH+8abtTE1Pi6jizo" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.14.7/umd/popper.min.js" integrity="sha384-UO2eT0CpHqdSJQ6hJty5KVphtPhzWj9WO1clHTMGa3JDZwrnQq4sF86dIHNDz0W1" crossorigin="anonymous"></script>
    <script src="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/js/bootstrap.min.js" integrity="sha384-JjSmVgyd0p3pXB1rRibZUAYoIIy6OrQ6VrjIEaFf/nJGzIxFDsf4x0xIM+B07jRM" crossorigin="anonymous"></script>
</head>
<body>
  <nav class="navbar navbar-inverse">
    <div class="container-fluid">
      <div class="navbar-header">
        <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-2">
          <span class="sr-only">Toggle navigation</span>
          <span class="icon-bar"></span>
          <span class="icon-bar"></span>
          <span class="icon-bar"></span>
        </button>
        <a class="navbar-brand" href="bonus-index.html">Home</a>
      </div>
  
      <div class="collapse navbar-collapse" id="bs-example-navbar-collapse-2">
        <ul class="nav navbar-nav">
          <li class="active"><a href="https://www.linkedin.com/in/wei-chester-zhu-84b336109/" target="_blank">LinkedIn<span class="sr-only">(current)</span></a></li>
          <li><a href="https://scholar.google.com/citations?view_op=list_works&hl=en&user=qj8pqxEAAAAJ&gmla=AJsN-F69QaBARR4vy3Duy9U_MeS0wj7i1UsNiJWxCVf_zm7TuRVTzUeiPLaALc6SFt7LSnJpJo9J0vV8Nfjv-_4IJO479-0srI15F4MRxqfKLuvcBV3_iQZk3voBcS5XDuipMGrB7E-R" target="_blank">Google Scholar</a></li>
          <li><a href="https://github.com/wzhu0815" target="_blank">GitHub</a></li>
          <li class="dropdown">
            <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">Research <span class="caret"></span></a>
            <ul class="dropdown-menu" role="menu">
              <li><a href="mbi.html">Mechanism-based Inactivators</a></li>
              <li class="divider"></li>
              <li><a href="ki.html">Kinase Inhibitors</a></li>
              <li class="divider"></li>
              <li><a href="ch.html">C-H Activation Methodology</a></li>
           
            </ul>
          </li>
        </ul>
        <ul class="nav navbar-nav navbar-right">
          <li><a href="mailto:wei.zhu@northwestern.com">Email Me</a></li>
        </ul>
      </div>
    </div>
  </nav>

    <div class="container">
        <div class="row">
          <div class="col-md-7">
              <h2 class="cadetblue">Kinase Inhibitors</h2>
              <hr>
              <a href="https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b00076"  target="_blank"><img src="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/medium/jm-2017-00076u_0015.gif" alt="Kinase Inhibitors"></a>
            <div class="row">
              <div class="col-md">
                <p>A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast growth factor receptors (FGFR), which was subsequently validated by in vitro experiments. The structure–activity relationship (SAR) of its analogues was then explored to afford novel FGFR inhibitors 2a–2p and 3a–3q. Among them, 3m showed potent inhibition against FGFR1, 2, and 3. Interestingly, compound 3m not only inhibited various phosphorylation and downstream signaling across different oncogenic forms in FGFR-overactivated cancer cells but also showed nanomolar level inhibition against several other NSCLC-related oncogene kinases, including RET, EGFR, EGFR/T790M/L858R, DDR2, and ALK. Finally, in vivo pharmacology evaluations of 3m showed significant antitumor activity (TGI = 66.1%) in NCI-H1581 NSCLC xenografts with a good pharmacokinetic profile.</p>
                <a href="https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.7b00076"  target="_blank"> J. Med. Chem., 2017, 60, 6018-6035. </a>
                <hr>
                <h5>Other Related Publications:</h5>
                <ol>
                    <li><a href="https://pubs.acs.org/doi/10.1021/ml5004876" target="_blank"> <p class = 'justify'>Li, C. P.; Ai, J.; Zhang, D. Y.; Peng, X.; Chen, X.; Gao, Z. W.; Su, Y.; Zhu, W.; Ji, Y. C.; Chen, X. Y.; Geng, M. Y.; Liu, H., Design, Synthesis, and Biological Evaluation of Novel Imidazo 1,2-a pyridine Derivatives as Potent c-Met Inhibitors. Acs. Med. Chem. Lett. 2015, 6, 507-512. </p></a></li>
                    <li><a href="https://www.nature.com/articles/aps201525" target="_blank"> <p class = 'justify'>Guo, X. B.; Zhu, W.; Chen, X. J.; Tong, L. J.; Peng, X.; Huang, M.; Liu, H. C.; Liu, H.; Ding, J., DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro. Acta pharmacologica Sinica, 2015, 36, 1266-1276.  </p></a></li>
                    <li><a href="https://www.sciencedirect.com/science/article/abs/pii/S0960894X13002138?via%3Dihub" target="_blank"> <p class = 'justify'>Zhang, D.; Ai, J.; Liang, Z.; Zhu, W.; Peng, X.; Chen, X.; Ji, Y.; Jiang, H.; Luo, C.; Geng, M.; Liu, H., Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors. Bioorganic Med.Chem. Lett. 2013, 23, 2408-2413. </p></a></li>
                   
                </ol>
              </div>
            </div>
          </div>
          <div class="col-md-1"></div>
          <div class="col-md-4">
            <h2 class="cadetblue">Research</h2>
            <hr>
              <h5><a href="mbi.html">Mechanism-based Inactivators</a></h5>
                <hr> 
                  <h5><a href="ki.html">Kinase Inhibitors</a></h5>
                <hr>
              <h5><a href="ch.html">C-H Activation Methodology</a></h5>
                <hr>
               
          </div>
  
    </div>
    </div>
</body>

</html>